【實用醫療app】St. Gallen Report 2013|最夯免費app-綠色工廠好玩App

This app presents a 25-page report of 13th St. Gallen International Breast Cancer Consensus Conference highlighting some of the controversial areas discussed during this meeting and is intended for healthcare professionals. The recognition that early breast cancer is a spectrum of diseases each requiring a specific systemic therapy guided the consensus conference. The meeting comprised of 3,600 participants from nearly 90 countries worldwide, which included clinical oncologists, pathologists, surgeons, gynaecologists, epidemiologists, breast cancer nurses and basic scientists. The consensus conference was co-chaired by Aron Goldhirsch (Switzerland/Italy) and Eric Winer (USA). The consensus was generated when panel members considered and voted on a number of questions in key areas of controversy.Educational content centred on the primary and multidisciplinary treatment approach of early breast cancer. On the final day, the meeting culminated with the St. Gallen Breast Cancer Treatment Consensus, which was established by the world’s most skilled opinion leaders in the field of breast cancer treatment.The principal aim of the 2013 St Gallen consensus conference was to provide rational recommendations for personalising the approach to treatment of early breast cancer in women. The key issues that were highlighted included:1. Tumour biology to determine responsiveness to various treatments2. Tumour extent to estimate the level of benefit when justifying treatment for the individual patient3. Estimates of the risks of therapy and patient preference to define preferred managementThe areas of controversy discussed during the meeting were: 1. Surgery of the primary2. Surgery of the axilla3. Radiation - partial breast, post-mastectomy, nodal areas, advanced technologies4. Pathology5. Multigene signatures6. Stroma - extracellular matrix and prognosis7. Endocrine therapies—ovarian suppression, tamoxifen, aromatase inhibitors8. Chemotherapies - luminal A, duration, regimen9. Anti-HER2 therapies - combination, duration10. Neo-adjuvant systemic therapy11. Bisphosphonates - anti-tumour effects12. Follow-up after early breast cancer